57.56
0.87%
0.4934
전일 마감가:
$57.07
열려 있는:
$57.53
하루 거래량:
230.26K
Relative Volume:
0.20
시가총액:
$9.60B
수익:
$29.52M
순이익/손실:
$-519.21M
주가수익비율:
-17.66
EPS:
-3.26
순현금흐름:
$-520.21M
1주 성능:
+0.34%
1개월 성능:
+20.55%
6개월 성능:
+45.15%
1년 성능:
+176.89%
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
RVMD | 57.56 | 9.60B | 29.52M | -519.21M | -520.21M | -3.26 |
VRTX | 447.45 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-16 | 재확인 | Needham | Buy |
2024-07-12 | 개시 | Barclays | Overweight |
2024-07-08 | 개시 | Jefferies | Buy |
2024-04-12 | 재확인 | Needham | Buy |
2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-03-11 | 개시 | Piper Sandler | Overweight |
2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
2024-01-04 | 개시 | Wedbush | Outperform |
2023-11-16 | 개시 | Raymond James | Outperform |
2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-12-14 | 개시 | Needham | Buy |
2022-10-21 | 개시 | Oppenheimer | Outperform |
2022-05-20 | 개시 | BofA Securities | Neutral |
2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
2021-09-23 | 개시 | Stifel | Hold |
2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
2021-05-18 | 개시 | Goldman | Buy |
2020-05-21 | 개시 | H.C. Wainwright | Buy |
2020-03-09 | 개시 | Cowen | Outperform |
2020-03-09 | 개시 | Guggenheim | Buy |
2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $61.00 Average Price Target from Brokerages - Defense World
Revolution Medicines executive sells shares worth $977,508 By Investing.com - Investing.com Australia
Revolution Medicines executive sells shares worth $977,508 - Investing.com
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline By Investing.com - Investing.com Australia
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline - Investing.com India
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month HighStill a Buy? - MarketBeat
HC Wainwright Issues Pessimistic Estimate for RVMD Earnings - MarketBeat
What is Wedbush's Forecast for RVMD FY2024 Earnings? - MarketBeat
Revolution Medicines' general counsel sells $360,000 in stock - Investing.com India
Revolution Medicines Stock Soars to All-Time High of $60.53 By Investing.com - Investing.com Canada
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight - Yahoo Finance
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Wellington Management Group LLP Reduces Stake in Revolution Medi - GuruFocus.com
Revolution Medicines' general counsel sells $360,000 in stock By Investing.com - Investing.com UK
Revolution Medicines Stock Soars to All-Time High of $60.53 - Investing.com
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress By Investing.com - Investing.com Australia
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress - Investing.com
HC Wainwright Issues Negative Outlook for RVMD Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus.com
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports Q3 2024 Results and Progress - TipRanks
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark A. Goldsmith sells $3.88 million in stock - Investing.com Canada
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada
(RVMD) Long Term Investment Analysis - Stock Traders Daily
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com South Africa
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times
Revolution Medicines stock hits 52-week high at $51.01 - Investing.com
Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace
Revolution Medicines reports positive RMC-9805 study results - Investing.com India
Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):